PsiOxus begins ovarian cancer trial of paclitaxel with oncolytic virus enadenotucirev

UK-based PsiOxus Therapeutics (PsiOxus) has started its Octave trial of paclitaxel combined with the oncolytic virotherapy enadenotucirev to treat patients with ovarian cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news